OTCPK:MDVX

Stock Analysis Report

Executive Summary

MedoveX Corp. designs and markets medical devices for commercial use primarily in the United States and Europe.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.

Share Price & News

How has MedoveX's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-12.5%

MDVX

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

-15.5%

MDVX

11.9%

US Medical Equipment

5.9%

US Market


Shareholder returns

MDVXIndustryMarket
7 Day-12.5%-0.003%1.3%
30 Day-13.4%-3.0%-1.9%
90 Day-33.0%-0.6%-1.8%
1 Year-15.5%-15.5%12.8%11.9%8.3%5.9%
3 Year-72.9%-72.9%69.6%64.5%45.6%36.2%
5 Yearn/a129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is MedoveX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MedoveX undervalued compared to its fair value and its price relative to the market?

3.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate MDVX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MDVX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDVX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MDVX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MDVX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDVX is good value based on its PB Ratio (3.5x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is MedoveX forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MDVX's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if MDVX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MDVX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MDVX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has MedoveX performed over the past 5 years?

-5.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MDVX is unprofitable, and losses have increased over the past 5 years at a rate of -5.1% per year.

Accelerating Growth: Unable to compare MDVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDVX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: MDVX has a negative Return on Equity (-84.21%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MDVX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MDVX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is MedoveX's financial position?


Financial Position Analysis

Short Term Liabilities: MDVX's short term assets ($3.2M) do not cover its short term liabilities ($3.5M)

Long Term Liabilities: MDVX's short term assets (3.2M) exceeds its long term liabilities (629.6K)


Debt to Equity History and Analysis

Debt Level: MDVX's debt to equity ratio (8.8%) is considered satisfactory

Reducing Debt: MDVX's debt to equity ratio has increased from 0% to 8.8% over the past 5 years.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDVX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MDVX has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.3% each year.


Next Steps

Dividend

What is MedoveX's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MDVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MDVX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MDVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDVX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDVX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of MedoveX's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Bill Horne (64yo)

0.8yrs

Tenure

US$153,333

Compensation

Mr. William E. Horne also known as,Bill is the Chief Executive Officer and Chairman at MedoveX Corp. since October 9, 2018. Mr. Horne is a founder and former Chief Executive Officer and Chairman of the Bo ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Insufficient data to compare Bill's compensation with company performance.


Management Age and Tenure

0.6yrs

Average Tenure

39yo

Average Age

Experienced Management: MDVX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Age and Tenure

0.5yrs

Average Tenure

64yo

Average Age

Experienced Board: MDVX's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Steve Gorlin (81yo)

    Co-Founder & Consultant

    • Tenure: 1.9yrs
  • Jill Schweiger

    Senior Vice President of Regulatory

    • Tenure: 2.7yrs
  • Briley Cienkosz (35yo)

    Chief Marketing Officer

    • Tenure: 0.08yrs
  • Jeff Wright (36yo)

    Controller

    • Tenure: 1.9yrs
    • Compensation: US$140.00k
  • Gary Mancini (38yo)

    Chief Relationship Officer

    • Tenure: 0.08yrs
  • Bill Horne (64yo)

    CEO & Chairman

    • Tenure: 0.8yrs
    • Compensation: US$153.33k
  • Jeremy Daniel (42yo)

    Chief Financial Officer

    • Tenure: 0.4yrs
  • Ann Miller (39yo)

    Chief Operating Officer

    • Tenure: 0.08yrs

Board Members

  • Ray Monteleone (71yo)

    Director

    • Tenure: 0.5yrs
  • Michael Yurkowsky (46yo)

    Director

    • Tenure: 0.5yrs
  • Bill Horne (64yo)

    CEO & Chairman

    • Tenure: 0.8yrs
    • Compensation: US$153.33k

Company Information

MedoveX Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MedoveX Corp.
  • Ticker: MDVX
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$35.105m
  • Shares outstanding: 98.89m
  • Website: https://www.MedoveX.com

Number of Employees


Location

  • MedoveX Corp.
  • 3060 Royal Boulevard South
  • Suite 150
  • Alpharetta
  • Georgia
  • 30022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDVXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2015

Biography

MedoveX Corp. designs and markets medical devices for commercial use primarily in the United States and Europe. The company offers DenerveX device, a disposable single-use kit for the treatment of various  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/04 00:50
End of Day Share Price2019/07/03 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.